Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

NCT07297238 · Recruiting

Last updated 2026-05-28

This clinical trial is testing how a medication called GLP-1 affects gut health in people with short bowel syndrome and intestinal failure.

Status Recruiting Currently enrolling participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 20 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2026-01 · est. completion 2026-05

Where 2 sites · China

What this study is testing ClinicalTrials.gov NCT07297238 ↗

Description as written by the study sponsor.

Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.

Treatments tested

GLP-1 Receptor Agonists also known as GLP-1RAs Drug

GLP-1 receptor agonists (semaglutide) are medications that mimic the action of the native human hormone glucagon-like peptide-1 (GLP-1). The recommended dosage is 0.25 mg administered subcutaneously once weekly.

Main thing measured	Serum Biomarkers of Intestinal Barrier Function
Sponsor	Jinling Hospital, China
Conditions studied	Short Bowel Syndrome (SBS), Intestinal Failure
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07297238 ↗